Company profile: Endonovo Therapeutics
1.1 - Company Overview
Company description
- Provider of off-the-shelf regenerative products and non-invasive electroceutical therapies, including SofPulse, a targeted microcurrent device for reducing swelling and accelerating recovery after surgery; PEMF-based treatments for cardiovascular and CNS disorders; a clinical trial in ischemic cardiomyopathy; and TVEMF technologies to mobilize stem cells and promote regeneration.
Products and services
- Electroceutical Therapy: A non-invasive, PEMF-based modality that stimulates tissue healing and addresses cardiovascular diseases and CNS disorders by delivering pulsed electromagnetic fields tuned for therapeutic regeneration
- SofPulse: A microcurrent-based device that targets swelling and accelerates recovery after procedures such as breast reconstruction by delivering localized microcurrents to affected tissues
- TVEMF Technologies: Space-derived electromagnetic systems that use time-varying frequencies to mobilize stem cells and drive regeneration, engineered for promoting tissue repair via controlled TVEMF exposure
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Endonovo Therapeutics
OtiTopic
HQ: United States
Website
- Description: Provider of drug delivery and drug-device development services as a pharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OtiTopic company profile →
FlowMedica
HQ: United States
Website
- Description: Provider of intravascular systems for implementing targeted renal therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full FlowMedica company profile →
WhiteSwell
HQ: Ireland
Website
- Description: Provider of science-driven solutions to improve treatment of acute decompensated heart failure, addressing a leading cause of hospitalization and emergency room visits by investigating the therapeutic potential of the lymphatic system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full WhiteSwell company profile →
Marea Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology therapies leveraging human genetics to develop next-generation treatments for cardiometabolic diseases. Pipeline includes MAR001, a monoclonal antibody targeting ANGPTL4 to reduce remnant cholesterol and triglycerides and improve adipose tissue function (Phase 2), MAR002, an anti-growth hormone receptor antibody for acromegaly, and undisclosed discovery programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Marea Therapeutics company profile →
DeVoro Medical
HQ: United States
Website
- Description: Provider of thrombectomy medical devices to restore blood flow, including the WOLF Thrombectomy Platform that captures and removes blood clots from the arterial and venous systems using finger-like prongs, without the need for a console or lytic agents.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DeVoro Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Endonovo Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Endonovo Therapeutics
2.2 - Growth funds investing in similar companies to Endonovo Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Endonovo Therapeutics
4.2 - Public trading comparable groups for Endonovo Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →